Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - A pilot study

Theresa Hautz, Christoph Krapf, Johanna Grahammer, Bettina Zelger, Tilman Hickethier, Christoph Seger, Nadine Eberhart, Christoph Wallner, Franka Messner, Katja Kotsch, Andrea Griesmacher, Gerald Brandacher, Wp Andrew Lee, Raimund Margreiter, Johann Pratschke, Hartmut Glossmann, Stefan Schneeberger

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Kv1.3-channels are critically involved in activation and function of effector memory T cells. Blocking Kv1.3-channels was investigated for its effect on skin rejection in a rat limb-transplantation-model. Animals received the Kv1.3-blocker correolide C systemically or locally as intra-graft-treatment in combination with tacrolimus. Systemic (intraperitoneal) administration of correolide C resulted in slight, but significant prolongation of allograft survival compared with untreated and placebo treated controls. In 4/6 correolide C treated animals, histology showed an intact epidermis and a mild infiltrate by day 10. High correolide C plasma trough levels correlated with prolonged allograft survival. A decrease in CD4+ and CD8+ effector memory T cells was observed in allograft skin, peripheral blood and the spleen on day 5. When applied subcutaneously in combination with systemic tacrolimus (30 days+/-anti-lymphocyte serum) detectable, but insignificant prolongation of graft survival was achieved. 2/5 animals showed an intact epidermis and a mild infiltrate until day 45. Tapering systemic tacrolimus and weaning on day 50 resulted in rejection by day 55, regardless of local correolide C treatment. Subcutaneous injection did not lead to systemic plasma levels. The Kv1.3-channel is a potential drug target worth exploring in more detail for immunosuppression in vascularized composite allotransplantation.

Original languageEnglish (US)
Pages (from-to)552-561
Number of pages10
JournalTransplant International
Volume26
Issue number5
DOIs
StatePublished - May 1 2013
Externally publishedYes

Fingerprint

Kv1.3 Potassium Channel
Vascularized Composite Allotransplantation
Immunosuppression
Tacrolimus
Allografts
Epidermis
T-Lymphocytes
Skin
Graft Survival
Subcutaneous Injections
Weaning
Histology
Spleen
Extremities
Transplantation
Placebos
correolide
Lymphocytes
Transplants
Therapeutics

Keywords

  • Correolide C
  • effector memory T cells
  • Kv1.3 channel blocker
  • skin rejection
  • targeted therapy
  • vascularized composite allotransplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Hautz, T., Krapf, C., Grahammer, J., Zelger, B., Hickethier, T., Seger, C., ... Schneeberger, S. (2013). Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - A pilot study. Transplant International, 26(5), 552-561. https://doi.org/10.1111/tri.12080

Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - A pilot study. / Hautz, Theresa; Krapf, Christoph; Grahammer, Johanna; Zelger, Bettina; Hickethier, Tilman; Seger, Christoph; Eberhart, Nadine; Wallner, Christoph; Messner, Franka; Kotsch, Katja; Griesmacher, Andrea; Brandacher, Gerald; Lee, Wp Andrew; Margreiter, Raimund; Pratschke, Johann; Glossmann, Hartmut; Schneeberger, Stefan.

In: Transplant International, Vol. 26, No. 5, 01.05.2013, p. 552-561.

Research output: Contribution to journalArticle

Hautz, T, Krapf, C, Grahammer, J, Zelger, B, Hickethier, T, Seger, C, Eberhart, N, Wallner, C, Messner, F, Kotsch, K, Griesmacher, A, Brandacher, G, Lee, WA, Margreiter, R, Pratschke, J, Glossmann, H & Schneeberger, S 2013, 'Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - A pilot study', Transplant International, vol. 26, no. 5, pp. 552-561. https://doi.org/10.1111/tri.12080
Hautz, Theresa ; Krapf, Christoph ; Grahammer, Johanna ; Zelger, Bettina ; Hickethier, Tilman ; Seger, Christoph ; Eberhart, Nadine ; Wallner, Christoph ; Messner, Franka ; Kotsch, Katja ; Griesmacher, Andrea ; Brandacher, Gerald ; Lee, Wp Andrew ; Margreiter, Raimund ; Pratschke, Johann ; Glossmann, Hartmut ; Schneeberger, Stefan. / Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - A pilot study. In: Transplant International. 2013 ; Vol. 26, No. 5. pp. 552-561.
@article{079477c16be74e62b6e25ae50ea0bfab,
title = "Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - A pilot study",
abstract = "Kv1.3-channels are critically involved in activation and function of effector memory T cells. Blocking Kv1.3-channels was investigated for its effect on skin rejection in a rat limb-transplantation-model. Animals received the Kv1.3-blocker correolide C systemically or locally as intra-graft-treatment in combination with tacrolimus. Systemic (intraperitoneal) administration of correolide C resulted in slight, but significant prolongation of allograft survival compared with untreated and placebo treated controls. In 4/6 correolide C treated animals, histology showed an intact epidermis and a mild infiltrate by day 10. High correolide C plasma trough levels correlated with prolonged allograft survival. A decrease in CD4+ and CD8+ effector memory T cells was observed in allograft skin, peripheral blood and the spleen on day 5. When applied subcutaneously in combination with systemic tacrolimus (30 days+/-anti-lymphocyte serum) detectable, but insignificant prolongation of graft survival was achieved. 2/5 animals showed an intact epidermis and a mild infiltrate until day 45. Tapering systemic tacrolimus and weaning on day 50 resulted in rejection by day 55, regardless of local correolide C treatment. Subcutaneous injection did not lead to systemic plasma levels. The Kv1.3-channel is a potential drug target worth exploring in more detail for immunosuppression in vascularized composite allotransplantation.",
keywords = "Correolide C, effector memory T cells, Kv1.3 channel blocker, skin rejection, targeted therapy, vascularized composite allotransplantation",
author = "Theresa Hautz and Christoph Krapf and Johanna Grahammer and Bettina Zelger and Tilman Hickethier and Christoph Seger and Nadine Eberhart and Christoph Wallner and Franka Messner and Katja Kotsch and Andrea Griesmacher and Gerald Brandacher and Lee, {Wp Andrew} and Raimund Margreiter and Johann Pratschke and Hartmut Glossmann and Stefan Schneeberger",
year = "2013",
month = "5",
day = "1",
doi = "10.1111/tri.12080",
language = "English (US)",
volume = "26",
pages = "552--561",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - A pilot study

AU - Hautz, Theresa

AU - Krapf, Christoph

AU - Grahammer, Johanna

AU - Zelger, Bettina

AU - Hickethier, Tilman

AU - Seger, Christoph

AU - Eberhart, Nadine

AU - Wallner, Christoph

AU - Messner, Franka

AU - Kotsch, Katja

AU - Griesmacher, Andrea

AU - Brandacher, Gerald

AU - Lee, Wp Andrew

AU - Margreiter, Raimund

AU - Pratschke, Johann

AU - Glossmann, Hartmut

AU - Schneeberger, Stefan

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Kv1.3-channels are critically involved in activation and function of effector memory T cells. Blocking Kv1.3-channels was investigated for its effect on skin rejection in a rat limb-transplantation-model. Animals received the Kv1.3-blocker correolide C systemically or locally as intra-graft-treatment in combination with tacrolimus. Systemic (intraperitoneal) administration of correolide C resulted in slight, but significant prolongation of allograft survival compared with untreated and placebo treated controls. In 4/6 correolide C treated animals, histology showed an intact epidermis and a mild infiltrate by day 10. High correolide C plasma trough levels correlated with prolonged allograft survival. A decrease in CD4+ and CD8+ effector memory T cells was observed in allograft skin, peripheral blood and the spleen on day 5. When applied subcutaneously in combination with systemic tacrolimus (30 days+/-anti-lymphocyte serum) detectable, but insignificant prolongation of graft survival was achieved. 2/5 animals showed an intact epidermis and a mild infiltrate until day 45. Tapering systemic tacrolimus and weaning on day 50 resulted in rejection by day 55, regardless of local correolide C treatment. Subcutaneous injection did not lead to systemic plasma levels. The Kv1.3-channel is a potential drug target worth exploring in more detail for immunosuppression in vascularized composite allotransplantation.

AB - Kv1.3-channels are critically involved in activation and function of effector memory T cells. Blocking Kv1.3-channels was investigated for its effect on skin rejection in a rat limb-transplantation-model. Animals received the Kv1.3-blocker correolide C systemically or locally as intra-graft-treatment in combination with tacrolimus. Systemic (intraperitoneal) administration of correolide C resulted in slight, but significant prolongation of allograft survival compared with untreated and placebo treated controls. In 4/6 correolide C treated animals, histology showed an intact epidermis and a mild infiltrate by day 10. High correolide C plasma trough levels correlated with prolonged allograft survival. A decrease in CD4+ and CD8+ effector memory T cells was observed in allograft skin, peripheral blood and the spleen on day 5. When applied subcutaneously in combination with systemic tacrolimus (30 days+/-anti-lymphocyte serum) detectable, but insignificant prolongation of graft survival was achieved. 2/5 animals showed an intact epidermis and a mild infiltrate until day 45. Tapering systemic tacrolimus and weaning on day 50 resulted in rejection by day 55, regardless of local correolide C treatment. Subcutaneous injection did not lead to systemic plasma levels. The Kv1.3-channel is a potential drug target worth exploring in more detail for immunosuppression in vascularized composite allotransplantation.

KW - Correolide C

KW - effector memory T cells

KW - Kv1.3 channel blocker

KW - skin rejection

KW - targeted therapy

KW - vascularized composite allotransplantation

UR - http://www.scopus.com/inward/record.url?scp=84876464461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876464461&partnerID=8YFLogxK

U2 - 10.1111/tri.12080

DO - 10.1111/tri.12080

M3 - Article

C2 - 23489391

AN - SCOPUS:84876464461

VL - 26

SP - 552

EP - 561

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 5

ER -